FDA Invites DMRF to Present on Deep Brain Stimulation for Dystonia


DMRF Chief Scientific Officer Dr. Jan Teller and Support Leader Marcie Povitsky represented the dystonia community at today's meeting of the Food & Drug Administration (FDA)’s Division of Neurological and Physical Medicine Devices about the use of deep brain stimulation (DBS) for the treatment of dystonia at the FDA's White Oak Campus in Silver Springs, Maryland. DBS is an important treatment option for many affected by dystonia and the DMRF is grateful to Division Director Dr. Carlos Pena and his team for the opportunity to talk about the current state of dystonia research, provide a patient perspective on DBS for dystonia, and learn about the device review and approval process.

The DMRF looks forward to continuing this conversation with the FDA and continuing to provide the dystonia community with a voice to this and other influential federal agencies as opportunities arise.

Past dialogue between the DMRF and FDA include providing remarks for a patient focused drug development initiative.

Accelerating Research & Inspiring Hope

The Dystonia Medical Research Foundation (DMRF) has served the dystonia community since 1976. Join us in our global effort to find a cure.